Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2017-05-30 Declaration of Voting R…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Flaggemelding Photocure ASA
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled 'Flaggemelding' (Flagging Announcement) and details a transaction where an insider, High Seas AS, sold shares of Photocure ASA on 30.05.2017. It explicitly states the resulting holding (14.99%) and references the requirement under the Securities Trading Act (§ 4-3). This type of filing, reporting personal share transactions by directors or major shareholders, directly corresponds to the 'Director's Dealing' category.
2017-05-30 Norwegian
Photocure ASA: Results for the first quarter of 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'First Quarter Report 2017' for the Photocure Group. It contains detailed financial statements, operational reviews, and management commentary for the three-month period ending in Q1 2017. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-23 English
Photocure ASA: Results for the first quarter of 2017
Investor Presentation Classification · 99% confidence The document is explicitly titled "RESULTS FOR FIRST QUARTER 2017" and contains detailed financial metrics, segment performance tables (e.g., Commercial franchise revenue, EBITDA margin), and operational updates specific to that quarter. This structure strongly indicates a comprehensive report covering a period shorter than a full year, which aligns with the definition of an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full Annual Report (10-K). The presence of a CEO/CFO presentation format further supports this being a formal quarterly results disclosure.
2017-05-23 English
Photocure ASA: Results for the first quarter of 2017
Earnings Release Classification · 100% confidence The document explicitly states it contains the "Results for the first quarter of 2017" and provides key financial metrics (revenue, EBITDA, net profit) for that period. It also mentions that the company will present its "interim report today" and provides details for a conference call/webcast. This content structure—summarizing quarterly financial performance and announcing a presentation/call—is characteristic of an Earnings Release (ER). Although it mentions the full financial report and presentation are enclosed, the primary function of this text is the initial announcement of the results, making ER the most appropriate classification over RPA or IR, as it contains the core results summary. Q1 2017
2017-05-23 English
Photocure ASA: Presentation of the first quarter 2017 results and the results from the Blue Light Flexible Cystoscopy with Hexvix®/Cysview® phase 3 study
Earnings Release Classification · 95% confidence The document is an announcement from Photocure ASA detailing the schedule and logistics for presenting its 'first quarter 2017 results' and results from a clinical study. It explicitly mentions a 'Q1 presentation' and an 'audio webcast and conference call' scheduled for the same day. This structure—announcing the release of periodic financial results alongside a presentation/call—strongly suggests an Earnings Release (ER) or a related event announcement. Since the document itself is an invitation/schedule for the presentation of the results, and not the full financial report (10-K or IR), it aligns best with the initial announcement of results. However, the document is primarily focused on the *presentation* event itself, which includes both the Q1 results presentation and a separate clinical study presentation. Given the context of presenting quarterly results, ER is a strong candidate, but the focus on the event logistics and the fact that it's an announcement about the presentation makes it similar to an RPA or CT announcement if the actual results aren't contained here. Since it is specifically about presenting the *results* (Q1), and not just announcing the *publication* of a report (RPA), and it is not the full transcript (CT), the most fitting category for the announcement of periodic financial results is Earnings Release (ER). The document length is short (2563 chars), but its content is clearly about the event where the results will be discussed, which is typical for an ER announcement package. Q1 2017
2017-05-16 English
Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 meeting in Boston
Regulatory Filings Classification · 95% confidence The document is a press release dated May 15th, 2017, announcing positive Phase 3 study results for a medical device/drug (Cysview®) presented at the American Urological Association (AUA) Annual Meeting. It details clinical findings, future regulatory plans (filing a supplemental NDA with the FDA), and provides background information on the condition and the product. This type of announcement, focusing on clinical trial results and immediate business/regulatory updates outside of standard periodic financial reporting (like 10-K or IR), is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to quarterly results, but since it's purely clinical/product news, RNS is the most appropriate catch-all for non-standard corporate disclosures. It is not a full report (10-K, AR, IR), a management discussion (MDA), or a presentation (IP). Given the context of a company announcing study data and regulatory next steps, RNS serves as the best fit among the provided options for a significant, non-periodic corporate announcement.
2017-05-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.